G. J. Alangaden, R. Thyagarajan, S. A. Gruber, K. Morawski, J. Garnick et al., Infectious complications after kidney transplantation: current epidemiology and associated risk factors, Clin Transplant. août, vol.20, issue.4, pp.401-410, 2006.

E. A. Hwang, M. J. Kang, S. Y. Han, S. B. Park, and H. C. Kim, Viral infection following kidney transplantation: long-term follow-up in a single center, Transplant Proc. sept, vol.36, issue.7, pp.2118-2127, 2004.

K. De-keyzer, S. Van-laecke, P. Peeters, and R. Vanholder, Human cytomegalovirus and kidney transplantation: a clinician's update, Am J Kidney Dis Off J Natl Kidney Found. juill, vol.58, issue.1, pp.118-144, 2011.

C. Legendre and M. Pascual, Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences, Clin Infect Dis Off Publ Infect Dis Soc Am. 1 mars, vol.46, issue.5, pp.732-772, 2008.

E. M. Hodson, C. A. Jones, A. C. Webster, G. Strippoli, P. G. Barclay et al., Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials, Lancet Lond Engl. 18 juin, vol.365, issue.9477, pp.2105-2120, 2005.

N. Singh, Optimization of outcomes related to cytomegalovirus in organ transplant recipients, Transplantation. 15 juill, vol.82, issue.1, pp.15-21, 2006.

S. K. Arthurs, A. J. Eid, R. A. Pedersen, W. K. Kremers, F. G. Cosio et al., Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation, Clin Infect Dis Off Publ Infect Dis Soc Am. 15 mars, vol.46, issue.6, pp.840-846, 2008.

A. Humar, Y. Lebranchu, F. Vincenti, E. A. Blumberg, J. D. Punch et al., The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. mai, vol.10, issue.5, pp.1228-1265, 2010.

C. N. Kotton, D. Kumar, A. M. Caliendo, S. Huprikar, S. Chou et al., The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation, Transplantation, vol.102, issue.6, pp.900-931, 2018.

T. Fehr, P. E. Cippà, and N. J. Mueller, Cytomegalovirus post kidney transplantation: prophylaxis versus pre-emptive therapy?, Transpl Int Off J Eur Soc Organ Transplant. déc, vol.28, issue.12, pp.1351-1357, 2015.

D. F. Florescu, F. Qiu, C. M. Schmidt, and A. C. Kalil, A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant, Clin Infect Dis Off Publ Infect Dis Soc Am. mars, vol.58, issue.6, pp.785-803, 2014.

P. Malvezzi, T. Jouve, and L. Rostaing, Negative Impact of CMV and BKV Infections on Kidney-Allograft Function at 1-Year PostTransplantation: Can it Be Changed by Modifying Immunosuppression?, EBioMedicine, vol.34, pp.2-3, 2018.

A. Blazquez-navarro, C. Dang-heine, N. Wittenbrink, C. Bauer, K. Wolk et al., CMV, and EBV Interactions and their Effect on Graft Function One Year Post-Renal Transplantation: Results from a Large Multi-Centre Study, EBioMedicine. août, vol.34, pp.113-134, 2018.

A. Egli, A. Humar, and D. Kumar, State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician, Clin Infect Dis Off Publ Infect Dis Soc Am. déc, vol.55, issue.12, pp.1678-89, 2012.

S. B. Kudchodkar, Y. Yu, T. G. Maguire, and J. C. Alwine, Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase, J Virol, vol.78, issue.20, pp.11030-11039, 2004.

P. Malvezzi, T. Jouve, and L. Rostaing, Use of Everolimus-based Immunosuppression to Decrease Cytomegalovirus Infection After Kidney Transplant, Exp Clin Transplant Off J Middle East Soc Organ Transplant. août, vol.14, issue.4, pp.361-367, 2016.

S. Havenith, S. L. Yong, K. Van-donselaar-van-der-pant, R. Van-lier, I. Ten-berge et al., Everolimustreated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporineor mycophenolate-treated patients, Transplantation. 15 janv, vol.95, issue.1, pp.184-91, 2013.

J. Pascual, S. P. Berger, O. Witzke, H. Tedesco, S. Mulgaonkar et al., Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation, J Am Soc Nephrol JASN. juill, vol.29, issue.7, pp.1979-91, 2018.

D. C. Brennan, C. Legendre, D. Patel, K. Mange, A. Wiland et al., Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.11, issue.11, pp.2453-62, 2011.

H. Tedesco-silva, F. C. Ferreira, A. Cristelli, M. Oliveira, N. Sandes-freitas et al., Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.15, issue.10, pp.2655-64, 2015.

S. G. Mallat, B. Y. Tanios, H. S. Itani, T. Lotfi, C. Mcmullan et al., CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and MetaAnalysis of Randomized, Controlled Trials, Clin J Am Soc Nephrol CJASN. 7 août, vol.12, issue.8, pp.1321-1357, 2017.

H. H. Hirsch and P. Randhawa, AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. mars, vol.13, pp.179-88, 2013.

T. Silva, H. Cibrik, D. Johnston, T. Lackova, E. Mange et al., Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. juin, vol.10, issue.6, pp.1401-1414, 2010.

T. Jouve, L. Rostaing, and P. Malvezzi, Place of mTOR inhibitors in management of BKV infection after kidney transplantation, J Nephropathol. janv, vol.5, issue.1, pp.1-7, 2016.

G. Basso, C. R. Felipe, M. P. Cristelli, M. Siliano, J. Viana et al., The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis, Transpl Infect Dis Off J Transplant Soc. août, vol.20, issue.4, p.12919, 2018.

T. V. De-sandes-freitas, P. Pinheiro, . Sales-ml-de, . Mbo, C. M. Girão et al., The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial, Transpl Int Off J Eur Soc Organ Transplant, vol.31, issue.12, pp.1345-56, 2018.

M. P. Cristelli, R. M. Esmeraldo, C. M. Pinto, T. V. Sandes-freitas, C. Felipe et al., The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients, Transpl Infect Dis Off J Transplant Soc. août, vol.20, issue.4, p.12907, 2018.

A. Devresse, M. Leruez-ville, A. Scemla, V. Avettand-fenoel, L. Morin et al., Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus, Transpl Infect Dis Off J Transplant Soc. avr, vol.20, issue.2, p.12846, 2018.

Y. Qazi, D. Shaffer, B. Kaplan, D. Y. Kim, F. L. Luan et al., Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. mai, vol.17, issue.5, pp.1358-69, 2017.

F. Shihab, Y. Qazi, S. Mulgaonkar, K. Mccague, D. Patel et al., Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. sept, vol.17, issue.9, pp.2363-71, 2017.

A. Kurdi, W. Martinet, D. Meyer, and G. , mTOR Inhibition and Cardiovascular Diseases: Dyslipidemia and Atherosclerosis, vol.102, pp.44-50, 2018.

G. J. Alangaden, R. Thyagarajan, S. A. Gruber, K. Morawski, J. Garnick et al., Infectious complications after kidney transplantation: current epidemiology and associated risk factors, Clin Transplant. août, vol.20, issue.4, pp.401-410, 2006.

E. A. Hwang, M. J. Kang, S. Y. Han, S. B. Park, and H. C. Kim, Viral infection following kidney transplantation: long-term follow-up in a single center, Transplant Proc. sept, vol.36, issue.7, pp.2118-2127, 2004.

K. De-keyzer, S. Van-laecke, P. Peeters, and R. Vanholder, Human cytomegalovirus and kidney transplantation: a clinician's update, Am J Kidney Dis Off J Natl Kidney Found. juill, vol.58, issue.1, pp.118-144, 2011.

C. Legendre, Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences

D. Lowance, H. H. Neumayer, C. M. Legendre, J. P. Squifflet, J. Kovarik et al., Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group, N Engl J Med. 13 mai, vol.340, pp.1462-70, 1999.

G. Opelz, B. Döhler, and A. Ruhenstroth, Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. juin, vol.4, issue.6, pp.928-964, 2004.

T. Reischig, P. Jindra, M. Svecová, S. Kormunda, K. Opatrný et al., The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection, J Clin Virol Off Publ Pan Am Soc Clin Virol. juin, vol.36, issue.2, pp.146-51, 2006.

A. Humar, K. J. Gillingham, W. D. Payne, D. L. Dunn, D. E. Sutherland et al., Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients, Transplantation. 27 déc, vol.68, issue.12, pp.1879-83, 1999.

I. Helanterä, T. Schachtner, C. Hinrichs, K. Salmela, L. Kyllönen et al., Current characteristics and outcome of cytomegalovirus infections after kidney transplantation, Transpl Infect Dis Off J Transplant Soc. août, vol.16, issue.4, pp.568-77, 2014.

J. A. Fishman, Infection in Organ Transplantation, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.17, issue.4, pp.856-79, 2017.

J. Hjelmesaeth, S. Sagedal, A. Hartmann, H. Rollag, T. Egeland et al., Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation, Diabetologia. sept, vol.47, issue.9, pp.1550-1556, 2004.

C. Courivaud, J. Bamoulid, J. Chalopin, E. Gaiffe, P. Tiberghien et al., Cytomegalovirus exposure and cardiovascular disease in kidney transplant recipients, J Infect Dis. 15 mai, vol.207, issue.10, pp.1569-75, 2013.

E. Razeghi, A. Hadadi, P. Khashayar, and G. Pourmand, Kaposi's sarcoma in renal transplantation: report of three cases, Clin Nephrol. févr, vol.71, issue.2, pp.214-220, 2009.

A. Humar and D. Snydman, AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. déc, vol.9, issue.4, pp.78-86, 2009.

, Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. nov, vol.9, issue.3, pp.1-155, 2009.

H. W. Sollinger, Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group, Transplantation. 15 août, vol.60, issue.3, pp.225-257, 1995.

N. Basic-jukic, P. Kes, L. J. Bubic-filipi, Z. Puretic, B. Brunetta et al., Does mycophenolate mofetil increase the incidence of cytomegalovirus disease compared with azathioprine after cadaveric kidney transplantation?, Transplant Proc. mars, vol.37, issue.2, pp.850-851, 2005.

S. Bataille, V. Moal, J. Gaudart, M. Indreies, R. Purgus et al., Cytomegalovirus risk factors in renal transplantation with modern immunosuppression, Transpl Infect Dis Off J Transplant Soc. déc, vol.12, issue.6, pp.480-488, 2010.

E. M. Hodson, C. A. Jones, A. C. Webster, G. Strippoli, P. G. Barclay et al., Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials, Lancet Lond Engl. 18 juin, vol.365, issue.9477, pp.2105-2120, 2005.

A. Humar, Y. Lebranchu, F. Vincenti, E. A. Blumberg, J. D. Punch et al., The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. mai, vol.10, issue.5, pp.1228-1265, 2010.

. Singh, Optimization of outcomes related to cytomegalovirus in organ transplant recipients

D. Sur,

S. K. Arthurs, A. J. Eid, R. A. Pedersen, W. K. Kremers, F. G. Cosio et al., Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation, Clin Infect Dis Off Publ Infect Dis Soc Am. 15 mars, vol.46, issue.6, pp.840-846, 2008.

A. P. Limaye, L. Corey, D. M. Koelle, C. L. Davis, and M. Boeckh, Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants, Lancet Lond Engl. 19 août, vol.356, issue.9230, pp.645-654, 2000.

A. Humar, T. Mazzulli, G. Moussa, R. R. Razonable, C. V. Paya et al., Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R-transplant recipients, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. mai, vol.5, issue.5, pp.1065-70, 2005.

S. A. Fayek, E. Beshears, R. Lieber, N. Alvey, A. Sauer et al., Extended Low-Dose Valganciclovir Is Effective Prophylaxis Against Cytomegalovirus in High-Risk Kidney Transplant Recipients With Near-Complete Eradication of Late-Onset Disease, Transplant Proc. août, vol.48, issue.6, pp.2056-2064, 2016.

F. Hashim, J. A. Gregg, and V. R. Dharnidharka, Efficacy of Extended Valganciclovir Prophylaxis in Preventing Cytomegalovirus Infection in Pediatric Kidney Transplantation, Open Urol Nephrol J, vol.7, pp.152-159, 2014.

C. N. Kotton, D. Kumar, A. M. Caliendo, S. Huprikar, S. Chou et al., The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation, Transplantation, vol.102, issue.6, pp.900-931, 2018.

A. Egli, A. Humar, and D. Kumar, State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician, Clin Infect Dis Off Publ Infect Dis Soc Am. déc, vol.55, issue.12, pp.1678-89, 2012.

T. Fehr, P. E. Cippà, and N. J. Mueller, Cytomegalovirus post kidney transplantation: prophylaxis versus pre-emptive therapy?, Transpl Int Off J Eur Soc Organ Transplant. déc, vol.28, issue.12, pp.1351-1357, 2015.
DOI : 10.1111/tri.12629

URL : https://onlinelibrary.wiley.com/doi/pdf/10.1111/tri.12629

D. F. Florescu, F. Qiu, C. M. Schmidt, and A. C. Kalil, A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant, Clin Infect Dis Off Publ Infect Dis Soc Am. mars, vol.58, issue.6, pp.785-803, 2014.

O. Witzke, M. Nitschke, M. Bartels, H. Wolters, G. Wolf et al., Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial, Transplantation, vol.102, issue.5, pp.876-82, 2018.

J. A. Khoury, G. A. Storch, D. L. Bohl, R. M. Schuessler, S. M. Torrence et al., Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. sept, vol.6, issue.9, pp.2134-2177, 2006.

D. Navarro, R. San-juan, O. Manuel, E. Giménez, M. Fernández-ruiz et al., Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey, Transpl Infect Dis Off J Transplant Soc. déc, vol.19, issue.6, 2017.

L. F. Lisboa, J. K. Preiksaitis, A. Humar, and D. Kumar, Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients, Transplantation, vol.92, issue.9, pp.1063-1071, 2011.

B. Blanco, N. Pascual, M. Venetz, J. Nseir, G. Meylan et al., Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients, Transplantation. 27 janv, vol.91, issue.2, pp.251-256, 2011.

M. T. Van-der-beek, S. P. Berger, A. Vossen, C. S. Van-der-blij-de-brouwer, R. R. Press et al., Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance, Transplantation. 15 févr, vol.89, issue.3, pp.320-326, 2010.

S. M. Flechner, J. Kobashigawa, and G. Klintmalm, Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity, Clin Transplant. févr, vol.22, issue.1, pp.1-15, 2008.
DOI : 10.1111/j.1399-0012.2007.00739.x

H. Ekberg, H. Tedesco-silva, A. Demirbas, S. Vítko, B. Nashan et al., Reduced exposure to calcineurin inhibitors in renal transplantation, N Engl J Med. 20 déc, vol.357, issue.25, pp.2562-75, 2007.

S. Vítko, R. Margreiter, W. Weimar, J. Dantal, D. Kuypers et al., Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. oct, vol.5, issue.10, pp.2521-2551, 2005.

M. I. Lorber, S. Mulgaonkar, K. Butt, E. Elkhammas, R. Mendez et al., Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study, Transplantation. 27 juill, vol.80, issue.2, pp.244-52, 2005.

B. Nashan, J. Curtis, C. Ponticelli, G. Mourad, J. Jaffe et al., Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study, Transplantation, vol.78, issue.9, pp.1332-1372, 2004.
DOI : 10.1097/01.tp.0000140486.97461.49

K. Budde, T. Becker, W. Arns, C. Sommerer, P. Reinke et al., Everolimus-based, calcineurininhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial, Lancet Lond Engl. 5 mars, vol.377, issue.9768, pp.837-884, 2011.

K. Budde, F. Lehner, C. Sommerer, P. Reinke, W. Arns et al., Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. janv, vol.15, issue.1, pp.119-147, 2015.

F. Shihab, Y. Qazi, S. Mulgaonkar, K. Mccague, D. Patel et al., Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. sept, vol.17, issue.9, pp.2363-71, 2017.

J. Pascual, S. P. Berger, O. Witzke, H. Tedesco, S. Mulgaonkar et al., Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation, J Am Soc Nephrol JASN. juill, vol.29, issue.7, pp.1979-91, 2018.

D. Cibrik, H. T. Silva, A. Vathsala, E. Lackova, C. Cornu-artis et al., Randomized trial of everolimusfacilitated calcineurin inhibitor minimization over 24 months in renal transplantation, Transplantation. 15 avr, vol.95, issue.7, pp.933-975, 2013.

Y. Qazi, D. Shaffer, B. Kaplan, D. Y. Kim, F. L. Luan et al., Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. mai, vol.17, issue.5, pp.1358-69, 2017.

R. M. Langer, R. Hené, S. Vitko, M. Christiaans, H. Tedesco-silva et al., Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation, Transpl Int Off J Eur Soc Organ Transplant. mai, vol.25, issue.5, pp.592-602, 2012.

J. Kumar, J. M. Bridson, A. Sharma, and A. Halawa, Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel, Exp Clin Transplant Off J Middle East Soc Organ Transplant. juin, vol.15, issue.3, pp.241-52, 2017.

P. Grimbert and O. Thaunat, mTOR inhibitors and risk of chronic antibody-mediated rejection after kidney transplantation: where are we now?, Transpl Int Off J Eur Soc Organ Transplant. juill, vol.30, issue.7, pp.647-57, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01911522

Z. Mithani, J. Gralla, O. Adebiyi, P. Klem, J. E. Cooper et al., De Novo Donor-Specific Antibody Formation in Tacrolimus-Based, Mycophenolate Versus Mammalian Target of Rapamycin Immunosuppressive Regimens, Exp Clin Transplant Off J Middle East Soc Organ Transplant, vol.16, issue.1, pp.23-30, 2018.

L. Biancone, B. Bussolati, G. Mazzucco, A. Barreca, E. Gallo et al., Loss of nephrin expression in glomeruli of kidney-transplanted patients under m-TOR inhibitor therapy, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.10, issue.10, pp.2270-2278, 2010.

E. Letavernier, P. Bruneval, S. Vandermeersch, J. Perez, C. Mandet et al., Sirolimus interacts with pathways essential for podocyte integrity, Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc -Eur Ren Assoc. févr, vol.24, issue.2, pp.630-638, 2009.

M. Oroszlán, M. Bieri, N. Ligeti, A. Farkas, B. Meier et al., Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway, Transpl Immunol. juill, vol.23, issue.3, pp.125-157, 2010.

H. Tedesco-silva, F. C. Ferreira, A. Cristelli, M. Oliveira, N. Sandes-freitas et al., Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.15, issue.10, pp.2655-64, 2015.

A. C. Wiseman, K. Mccague, Y. Kim, F. Geissler, and M. Cooper, The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. févr, vol.13, issue.2, pp.442-451, 2013.

B. Nashan and F. Citterio, Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature, Transplantation. 27 sept, vol.94, issue.6, pp.547-61, 2012.

S. Huber, C. J. Bruns, G. Schmid, P. C. Hermann, C. Conrad et al., Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis, Kidney Int. avr, vol.71, issue.8, pp.771-778, 2007.

H. Tedesco-silva, J. Pascual, O. Viklicky, N. Basic-jukic, E. Cassuto et al., Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study, Transplantation. 19 févr, 2019.

T. Silva, H. Cibrik, D. Johnston, T. Lackova, E. Mange et al., Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. juin, vol.10, issue.6, pp.1401-1414, 2010.

S. G. Mallat, B. Y. Tanios, H. S. Itani, T. Lotfi, C. Mcmullan et al., CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials, Clin J Am Soc Nephrol CJASN. 7 août, vol.12, issue.8, pp.1321-1357, 2017.

G. Zaza, P. Tomei, P. Ria, S. Granata, L. Boschiero et al., Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors, Clin Dev Immunol, p.403280, 2013.
DOI : 10.1155/2013/403280

URL : https://doi.org/10.1155/2013/403280

A. Kurdi, W. Martinet, D. Meyer, and G. , mTOR Inhibition and Cardiovascular Diseases: Dyslipidemia and Atherosclerosis, vol.102, pp.44-50, 2018.

B. Nashan, R. Gaston, V. Emery, M. D. Säemann, N. J. Mueller et al., Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients, Transplantation. 15 juin, vol.93, issue.11, pp.1075-85, 2012.

S. B. Kudchodkar, Y. Yu, T. G. Maguire, and J. C. Alwine, Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase, J Virol, vol.78, issue.20, pp.11030-11039, 2004.

P. Malvezzi, T. Jouve, and L. Rostaing, Use of Everolimus-based Immunosuppression to Decrease Cytomegalovirus Infection After Kidney Transplant, Exp Clin Transplant Off J Middle East Soc Organ Transplant. août, vol.14, issue.4, pp.361-367, 2016.

N. J. Moorman and T. Shenk, Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication, J Virol. mai, vol.84, issue.10, pp.5260-5269, 2010.
DOI : 10.1128/jvi.02733-09

URL : http://europepmc.org/articles/pmc2863801?pdf=render

K. Araki, A. P. Turner, V. O. Shaffer, S. Gangappa, S. A. Keller et al., mTOR regulates memory CD8 Tcell differentiation, Nature. 2 juill, vol.460, issue.7251, pp.108-120, 2009.
DOI : 10.1038/nature08155

URL : http://europepmc.org/articles/pmc2710807?pdf=render

S. Havenith, S. L. Yong, K. Van-donselaar-van-der-pant, R. Van-lier, I. Ten-berge et al., Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine-or mycophenolate-treated patients, Transplantation. 15 janv, vol.95, issue.1, pp.184-91, 2013.

D. C. Brennan, C. Legendre, D. Patel, K. Mange, A. Wiland et al., Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.11, issue.11, pp.2453-62, 2011.

T. V. De-sandes-freitas, P. Pinheiro, . Sales-ml-de, . Mbo, C. M. Girão et al., The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial, Transpl Int Off J Eur Soc Organ Transplant, vol.31, issue.12, pp.1345-56, 2018.

M. P. Cristelli, R. M. Esmeraldo, C. M. Pinto, T. V. Sandes-freitas, C. Felipe et al., The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients, Transpl Infect Dis Off J Transplant Soc. août, vol.20, issue.4, p.12907, 2018.

A. Devresse, M. Leruez-ville, A. Scemla, V. Avettand-fenoel, L. Morin et al., Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus, Transpl Infect Dis Off J Transplant Soc. avr, vol.20, issue.2, p.12846, 2018.

J. Pascual, A. Royuela, A. M. Fernández, I. Herrero, J. F. Delgado et al., Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients, Transpl Infect Dis Off J Transplant Soc. déc, vol.18, issue.6, pp.819-850, 2016.

. Basso, The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients wit, PubMed -NCBI

J. Radtke, N. Dietze, V. N. Spetzler, L. Fischer, E. Achilles et al., Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid, Transpl Infect Dis Off J Transplant Soc. févr, vol.18, issue.1, pp.79-88, 2016.

H. H. Hirsch and P. Randhawa, AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. mars, vol.13, pp.179-88, 2013.

A. Egli, L. Infanti, A. Dumoulin, A. Buser, J. Samaridis et al., Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors, J Infect Dis. 15 mars, vol.199, issue.6, pp.837-883, 2009.

P. M. Chesters, J. Heritage, and D. J. Mccance, Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues, J Infect Dis. avr, vol.147, issue.4, pp.676-84, 1983.

J. R. Scadden, A. Sharif, K. Skordilis, and R. Borrows, Polyoma virus nephropathy in kidney transplantation, World J Transplant. 24 déc, vol.7, issue.6, pp.329-367, 2017.

Z. M. El-zoghby, M. D. Stegall, D. J. Lager, W. K. Kremers, H. Amer et al., Identifying specific causes of kidney allograft loss, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. mars, vol.9, issue.3, pp.527-562, 2009.

J. Sellarés, D. G. De-freitas, M. Mengel, J. Reeve, G. Einecke et al., Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. févr, vol.12, issue.2, pp.388-99, 2012.

D. Sawinski and S. Goral, BK virus infection: an update on diagnosis and treatment, Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc -Eur Ren Assoc. févr, vol.30, issue.2, pp.209-226, 2015.

B. Demey, C. Tinez, C. François, F. Helle, G. Choukroun et al., Risk factors for BK virus viremia and nephropathy after kidney transplantation: A systematic review, J Clin Virol Off Publ Pan Am Soc Clin Virol. déc, vol.109, pp.6-12, 2018.

B. L. Kasiske, M. G. Zeier, J. R. Chapman, J. C. Craig, H. Ekberg et al., KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary, Kidney Int. févr, vol.77, issue.4, pp.299-311, 2010.

A. Liacini, M. E. Seamone, D. A. Muruve, and L. A. Tibbles, Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection, Transplantation. 27 déc, vol.90, issue.12, pp.1450-1457, 2010.

A. Egli, S. Köhli, M. Dickenmann, and H. H. Hirsch, Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. Transplantation, vol.88, pp.1161-1169, 2009.

V. R. Dharnidharka, W. S. Cherikh, and K. C. Abbott, An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States, Transplantation. 15 avr, vol.87, issue.7, pp.1019-1045, 2009.

J. Radtke, N. Dietze, L. Fischer, E. Achilles, J. Li et al., Incidence of BK polyomavirus infection after kidney transplantation is independent of type of immunosuppressive therapy, Transpl Infect Dis Off J Transplant Soc. déc, vol.18, issue.6, pp.850-855, 2016.

R. K. Wali, C. Drachenberg, H. H. Hirsch, J. Papadimitriou, A. Nahar et al., BK virus-associated nephropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression, Transplantation, vol.78, issue.7, pp.1069-73, 2004.

A. I. Sánchez-fructuoso, N. Calvo, I. Perez-flores, R. Valero, B. Rodríguez-sánchez et al., Mammalian target of rapamycin signal inhibitors could play a role in the treatment of BK polyomavirus nephritis in renal allograft recipients, Transpl Infect Dis Off J Transplant Soc. déc, vol.13, issue.6, pp.584-91, 2011.

J. Jacobi, A. Prignitz, M. Büttner, K. Korn, A. Weidemann et al., BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition, BMC Nephrol, vol.14, p.207, 2013.

N. Polanco, G. Monte, E. Folgueira, M. D. Morales, E. et al., Everolimusbased immunosuppression therapy for BK virus nephropathy, Transplant Proc. févr, vol.47, issue.1, pp.57-61, 2015.

, Using mTOR Inhibitors in the Prevention of BK Nephropathy -Full Text View -ClinicalTrials

, Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients -Full Text View -ClinicalTrials.gov

D. Sur,